# US 2022/0031913 A1 · Modified alginates for anti-fibrotic materials and applications

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0031913 A1
- Document ID: US20220031913A1
- Status: Published application
- Kind: A1
- Application number: 17/377,124
- Filed: 2021-07-15
- Published: 2022-02-03
- Earliest claimed: 2015-11-01
- Assignees: Massachusetts Institute of Technology; Children's Medical Center Corporation
- Applicants: Massachusetts Institute of Technology; The Children's Medical Center Corporation
- Inventors: Arturo Vegas; Joshua C. Doloff; Omid Veiseh; Minglin Ma; Robert S. Langer; Daniel G. Anderson
- Web page: https://patentgrep.com/patent/US20220031913A1

## CPC

- A61L 29/085: {Macromolecular materials}
- A61K 9/0024: {Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue (compositions for intravenous administration, normal injectable solutions or dispersions for, e.g. subcutaneous administration A61K9/0019; brain implants A61K9/0085; (coated) prostheses, catheters or stents A61L)}
- A61K 9/4816: {Wall or shell material}
- A61K 9/5036: {Polysaccharides, e.g. gums, alginate; Cyclodextrin}
- A61K 35/39: Pancreas; Islets of Langerhans (Langerhans cells of epidermis A61K35/36)
- A61K 47/36: Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61L 31/10: Macromolecular materials
- A61L 33/08: Polysaccharides
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- C07D 487/04: Ortho-condensed systems
- C08B 37/0084: {Guluromannuronans, e.g. alginic acid, i.e. D-mannuronic acid and D-guluronic acid units linked with alternating alpha- and beta-1,4-glycosidic bonds; Derivatives thereof, e.g. alginates}
- C12N 5/0012: {Cell encapsulation}
- C12N 5/0677: {Three-dimensional culture, tissue culture or organ culture; Encapsulated cells}
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- C08B: POLYSACCHARIDES; DERIVATIVES THEREOF (polysaccharides containing less than six saccharide radicals attached to each other by glycosidic linkages C07H; fermentation or enzyme-using processes C12P19/00; sugar industry C13; production of cellulose D21)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Covalently modified alginate polymers, possessing enhanced biocompatibility and tailored physiochemical properties, as well as methods of making and use thereof, are disclosed herein. The covalently modified alginates are useful as a matrix for coating of any material where reduced fibrosis is desired, such as encapsulated cells for transplantation and medical devices implanted or used in the body.

## Claims

### Claim at position 1

-32. (canceled)

### Claim 33

A composition comprising a preparation of alginate capsules encapsulating mammalian cells,
wherein at least 95% of the capsules in the preparation have a diameter between 1 mm and 4 mm, inclusive,
wherein the capsules comprise a singularly modified alginate polymer comprising one or more covalently modified monomers defined by Formula I
wherein —X—R1 is selected from the group consisting of:

### Claim 34 (depends on 33)

The composition of claim 33, wherein —X—R1 is

### Claim 35 (depends on 33)

The composition of claim 33, wherein the cells comprise stem cells, cells derived from stem cells, cells from a cell line, primary cells, reprogrammed cells, reprogrammed stem cells, cells derived from reprogrammed stem cells, or genetically engineered cells.

### Claim 36 (depends on 33)

The composition of claim 33, wherein the cells are neural cells, ganglion cells, retinal epithelial cells, adrenal medulla cells, lung cells, cardiac muscle cells, osteoclast cells, bone marrow cells, spleen cells, thymus cells, glandular cells, blood cells, myogenic cells, keratinocytes, or smooth muscle cells.

### Claim 37 (depends on 33)

The composition of claim 33, wherein the cells secrete a therapeutically effective substance.

### Claim 38 (depends on 33)

The composition of claim 33, wherein at least 95% of the capsules in the preparation have a diameter of 1 mm to 2 mm, inclusive.

### Claim 39 (depends on 38)

The composition of claim 38, wherein the modified alginate polymer is crosslinked ionically.

### Claim 40 (depends on 38)

The composition of claim 38, wherein the capsules further comprise an unmodified alginate.

### Claim 41 (depends on 40)

The composition of claim 40, wherein at least 95% of the capsules in the preparation have a sphere or sphere-like shape.

### Claim 42 (depends on 41)

The composition of claim 41, wherein the cells are genetically engineered to produce a protein or nucleic acid.

### Claim 43 (depends on 42)

The composition of claim 42, wherein the protein is a hormone, a growth factor, or an enzyme.

### Claim 44 (depends on 42)

The composition of claim 42, wherein the protein is an antigen or an antibody.

### Claim 45 (depends on 42)

The composition of claim 42, wherein the protein is a tumor antigen.

### Claim 46 (depends on 42)

The composition of claim 42, wherein the protein comprises the antigen binding domain of an antibody.

### Claim 47 (depends on 42)

The composition of claim 42, wherein the protein is a blood clotting factor.

### Claim 48 (depends on 42)

The composition of claim 42, wherein the protein is an enzyme useful to treat a lysosomal storage disorder.

### Claim 49 (depends on 48)

The composition of claim 48, wherein the enzyme is selected from the group consisting of cerebrosidase, beta-hexosaminidase A, alpha-galactosidase, alpha-iduronidase, iduronate sulfatase, an enzyme involved in heparan sulfate degradation, arylsulfatase B, galactose 6-sulfatase, and beta-galactosidase.

### Claim 50 (depends on 33)

A method of treating a disease or disorder in a human patient, comprising implanting or transplanting into the human patient a composition according to claim 33.

### Claim 51 (depends on 50)

The method of claim 50, wherein the disease is diabetes and the mammalian cells are insulin-producing cells derived from reprogrammed stem cells.

### Claim 52 (depends on 50)

The method of claim 50, wherein the disease is hemophilia and the mammalian cells are genetically engineered to produce a blood clotting factor.

### Claim 53 (depends on 50)

The method of claim 50, wherein the disease is Fabry disease and the cells are genetically engineered to produce alpha-galactosidase.

### Claim 54 (depends on 50)

The method of claim 50, wherein the disease is Hurler syndrome and the cells are genetically engineered to produce alpha-iduronidase.
